Gene tests on dogs boost hopes for haemophilia

November 19, 2013

Scientists on Tuesday said they had treated haemophilia in dogs by fixing a flawed gene, marking a step forward towards treating the condition in humans, too.

Haemophilia A, the most widespread form of the inherited bleeding disease, occurs in around one in 10,000 men.

It occurs through a malfunctioning gene, passed on through the maternal line, that causes a deficiency in a blood-clotting protein called Factor VIII.

There is currently no cure. Uncontrolled bleeding is treated by coagulant injection, although some patients' immune systema can react to this.

A team led by David Wilcox at the Medical College of Wisconsin in Milwaukee used a virus as a microscopic Trojan Horse in tests on dogs.

They tucked a functioning version of a gene called ITGA2B into a .

The virus was then used to "infect" three dogs with haemophilia A, delivering the good gene into stem cells that make platelets, or tiny cell fragments that clot the blood.

Two of the dogs that produced the highest levels of Factor VIII after the therapy had no episodes of severe bleeding throughout the two-and-a-half-year duration of the study.

None of the three dogs required drugs to suppress its after being given the new gene, according to the study, appearing in the journal Nature Communications.

Gene therapy is based on the idea that inherited diseases may be combatted by slotting in functioning to replace defective ones.

It burst on the medical scene in the late 1990s and is one of the most alluring areas of biotechnology, offering the theoretical promise of blocking or reversing inherited disease.

But this new frontier has also been hit by occasional setbacks, notably an unexpected or uncontrollable response from the immune system.

So far, successes have been few, limited to single-gene disorders—as opposed to complex multi-gene disorders that account for the commonest diseases.

In July, scientists in Italy said they had treated six children with metachromatic leukodystrophy, a disease of the nervous system which is caused by mutations in the ARSA gene.

Setbacks have included the death of an 18-year-old US volunteer, Jesse Gelsinger, in 1999, and the development of cancer among two French children treated for "bubble baby" syndrome, a chronic lack of .

Explore further: First gene therapy to go on sale in Europe in 2013

Related Stories

First gene therapy to go on sale in Europe in 2013

November 5, 2012

Dutch biotech company uniQure said Monday it would start selling the first human gene therapy to be approved in the West by mid-2013 and predicted an explosion of similar therapies to come.

One-two punch could be key in treating blindness

April 9, 2013

Researchers have discovered that using two kinds of therapy in tandem may be a knockout combo against inherited disorders that cause blindness. While their study focused on man's best friend, the treatment could help restore ...

Team takes first step toward macular dystrophy gene therapy

October 15, 2013

Vitelliform macular dystrophy, also known as Best disease, is one of a group of vision-robbing conditions called bestrophinopathies that affect children and young adults. Caused by inherited mutations in the BEST1 gene, these ...

Researchers identify way to increase gene therapy success

October 30, 2013

Scientists in The Research Institute at Nationwide Children's Hospital have found a way to overcome one of the biggest obstacles to using viruses to deliver therapeutic genes: how to keep the immune system from neutralizing ...

Recommended for you

New class of RNA tumor suppressors identified

November 23, 2015

A pair of RNA molecules originally thought to be no more than cellular housekeepers are deleted in over a quarter of common human cancers, according to researchers at the Stanford University School of Medicine. Breast cancer ...

Batten disease may benefit from gene therapy

November 11, 2015

In a study of dogs, scientists showed that a new way to deliver replacement genes may be effective at slowing the development of childhood Batten disease, a rare and fatal neurological disorder. The key may be to inject viruses ...

Molecular clocks control mutation rate in human cells

November 9, 2015

Every cell in the human body contains a copy of the human genome. Through the course of a lifetime all cells are thought to acquire mutations in their genomes. Some of the mutational processes generating these mutations do ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.